Markets:

Overview

News

Currencies

International

Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

36.00 -0.41 (-1.13%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

June 11, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony (HRMY) Q1 2026 Earnings Transcript ↗

June 01, 2026

Harmony (HRMY) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Harmony Biosciences to Participate in Upcoming Investor Conferences

May 27, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗

May 19, 2026

Bitgo Holdings provides digital asset infrastructure and custody services for institutional clients, supporting secure management at scale.

Via The Motley Fool

Topics Regulatory Compliance

Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 Revenue Meets Guidance, But EPS Miss and Elevated Spending Weigh on Shares ↗

May 07, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY): A Decent Value Play with Strong Fundamentals ↗

April 28, 2026

Via Chartmill

A beaten-down biotech just lost a meaningful backer — should you care? ↗

May 19, 2026

Harmony Biosciences develops therapies for rare neurological disorders, with WAKIX addressing excessive sleepiness in narcolepsy patients.

Via The Motley Fool

Topics Regulatory Compliance

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

May 07, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

April 16, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Quality at a Discount ↗

March 13, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Reports Q4 2025 Revenue In Line, Earnings Miss Amid Pipeline Investment ↗

February 24, 2026

Via Chartmill

Topics Earnings

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

April 14, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...

Via Finterra

Topics Economy Intellectual Property

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...

Via MarketMinute

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Compelling Value and Growth Pick ↗

February 20, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗

February 17, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime GARP Investment ↗

February 13, 2026

Via Chartmill

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...

Via MarketMinute

Topics Intellectual Property

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

April 02, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

March 31, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in Upcoming Investor Conferences

March 04, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences (HRMY) Earnings Transcript ↗

February 24, 2026

Harmony Biosciences (HRMY) Earnings Transcript

Via The Motley Fool

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

February 24, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

HRMY Stock Rises On Fresh FDA Approval For Wakix Tablets In Children But Wall Street Eyes Further Rally ↗

February 17, 2026

The FDA has approved Harmony’s Wakix tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

Via Stocktwits

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

February 17, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 10, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity ↗

February 01, 2026

This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested,...

Via The Motley Fool

Topics Regulatory Compliance

Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800 ↗

January 31, 2026

This bioscience company has had promising financials, yet one of its top executives exited his entire direct equity ownership in mid-January 2026.

Via The Motley Fool

Topics Regulatory Compliance

Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800 ↗

January 31, 2026

This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.